US Patent

US11446260 — Pharmaceutical composition of S-ketamine hydrochloride

Method of Use · Assigned to Janssen Pharmaceutica NV · Expires 2034-03-14 · 8y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects an aqueous formulation of S-ketamine hydrochloride for nasal administration without an antimicrobial preservative.

USPTO Abstract

The present invention is directed to an aqueous formulation of S-ketamine hydrochloride, preferably for nasal administration, wherein the formulation does not contain an antimicrobial preservative.

Drugs covered by this patent

esketamine-hydrochloride (ESKETAMINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4118`	—	esketamine-hydrochloride

Patent Metadata

Patent number: US11446260
Jurisdiction: US
Classification: Method of Use
Expires: 2034-03-14
Drug substance claim: No
Drug product claim: No
Assignee: Janssen Pharmaceutica NV
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.